Overview
Nara Lima practices practicing medicine in Recife, Brazil.
Their clinical expertise encompasses Severe Acute Respiratory Syndrome (SARS), COVID-19, Malnutrition, and Pneumonia.
They are actively involved in clinical research, co-authoring 31 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Nara R. Lima
Is Nara R. Lima a top-rated expert for Severe Acute Respiratory Syndrome (SARS)?
MediFind is an objective health platform that identifies experts based on real-world data. Nara R. Lima is classified as an Experienced expert for Severe Acute Respiratory Syndrome (SARS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Nara R. Lima participate in research or clinical trials?
Yes. Nara R. Lima has published 31 articles and abstracts on conditions like Severe Acute Respiratory Syndrome (SARS). You can view a list of Nara R. Lima's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- COVID-19Lima isExperienced. Learn about COVID-19.
- MalnutritionLima isExperienced. Learn about Malnutrition.
- PneumoniaLima isExperienced. Learn about Pneumonia.
- Severe Acute Respiratory Syndrome (SARS)